PMID-sentid	Pub_year	Sent_text		comp_official_name	comp_offsetprotein_name	organism	prot_offset
2112675-0	1990	Effect of pravastatin sodium, a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase, on very-low-density lipoprotein composition and kinetics in hyperlipidemia associated with experimental nephrosis.	Pravastatin	10-28	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	49-96	
2112675-1	1990	The effect of Pravastatin sodium (CS-514), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA R) on very-low-density lipoprotein (VLDL) composition and kinetics was studied in normal and experimental nephrotic rats under fasting conditions.	Pravastatin	14-32	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	111-120	
2112675-1	1990	The effect of Pravastatin sodium (CS-514), a new inhibitor of 3-hydroxy-3-methylglutaryl coenzyme A reductase (HMG-CoA R) on very-low-density lipoprotein (VLDL) composition and kinetics was studied in normal and experimental nephrotic rats under fasting conditions.	Pravastatin	34-40	3-hydroxy-3-methylglutaryl-CoA reductase	Rattus norvegicus	111-120	
2112675-2	1990	Nephrotic rats, induced by a single intraperitoneal injection of puromycin aminonucleoside (100 mg/kg body weight), had significantly higher plasma lipids and apoprotein (apo) B concentrations than controls.	Puromycin Aminonucleoside	65-90	apolipoprotein B	Rattus norvegicus	159-177	
2112675-6	1990	TG, cholesterol, phospholipid, and apo B concentrations in nephrotic VLDL were significantly reduced by Pravastatin treatment, whereas only TG was decreased in control VLDL.	Pravastatin	104-115	apolipoprotein B	Rattus norvegicus	35-40	
2112675-7	1990	Pravastatin reduced the apo B 100 + 95/48 ratio in nephrotic VLDL.	Pravastatin	0-11	apolipoprotein B	Rattus norvegicus	24-33